Thinking aloud
about the future.

The oversubscribed fund will target control investments in technology, life sciences, and advanced manufacturing businesses across North America and Europe. Commitments came from sovereign wealth funds, endowments, and family offices across 28 countries.

Our research team examines why near-term quantum advantage will arrive first in optimization and simulation — and what that means for allocators who are either over-exposed or completely absent from the space today.

The investment marks the firm's largest single venture commitment to date, accelerating BioSynth's AI-driven drug discovery platform which has already identified three first-in-class clinical candidates.

Digital infrastructure demand is growing faster than at any point in computing history. We analyze the supply-demand dynamics driving hyperscale data center valuations — and how disciplined investors should approach the space.

The new Singapore hub will serve as the firm's Asia-Pacific headquarters, housing investment teams focused on deeptech, life sciences, and infrastructure opportunities across Southeast Asia and the broader Indo-Pacific.

The GLP-1 wave is only the beginning. Our life sciences investment team maps the next generation of metabolic disease interventions — from next-generation peptides to microbiome-targeted therapies — and the investment implications for each.

Founding Partner Ron Jagannathan discusses how scientific training shapes investment discipline, why he believes the next decade of alpha will be earned by investors who understand technology at a deep level, and Stembassadors Capital's expansion plans.

The annual report documents the firm's progress against its 2030 net zero commitment, ESG integration across the portfolio, and the impact metrics of the STEM Impact Fund — which has now reached 4.2 million students globally.